Christopher Posner - Net Worth and Insider Trading
Christopher Posner Net Worth
The estimated net worth of Christopher Posner is at least $48,622 dollars as of 2024-11-29. Christopher Posner is the PRESIDENT AND CEO of Cara Therapeutics Inc and owns about 168,768 shares of Cara Therapeutics Inc (CARA) stock worth over $48,622. Details can be seen in Christopher Posner's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Christopher Posner has not made any transactions after 2024-11-04 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Christopher Posner
Christopher Posner Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Christopher Posner owns 2 companies in total, including Cara Therapeutics Inc (CARA) , and Zevra Therapeutics Inc (ZVRA) .
Click here to see the complete history of Christopher Posner’s form 4 insider trades.
Insider Ownership Summary of Christopher Posner
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CARA | Cara Therapeutics Inc | 2024-11-04 | director |
| ZVRA | Zevra Therapeutics Inc | 2022-11-28 | director |
Christopher Posner Latest Holdings Summary
Christopher Posner currently owns a total of 1 stock. Christopher Posner owns 168,768 shares of Cara Therapeutics Inc (CARA) as of November 4, 2024, with a value of $48,622.
Latest Holdings of Christopher Posner
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| CARA | Cara Therapeutics Inc | 2024-11-04 | 168,768 | 0.29 | 48,622 |
Holding Weightings of Christopher Posner
Christopher Posner Form 4 Trading Tracker
According to the SEC Form 4 filings, Christopher Posner has made a total of 14 transactions in Cara Therapeutics Inc (CARA) over the past 5 years, including 0 buys and 14 sells. The most-recent trade in Cara Therapeutics Inc is the sale of 3,668 shares on November 4, 2024, which brought Christopher Posner around $1,064.
Insider Trading History of Christopher Posner
- 1
Christopher Posner Trading Performance
Christopher Posner Ownership Network
Christopher Posner Owned Company Details
What does Cara Therapeutics Inc do?
Who are the key executives at Cara Therapeutics Inc?
Christopher Posner is the director of Cara Therapeutics Inc. Other key executives at Cara Therapeutics Inc include Chief Medical Officer Joana Goncalves , Sec'y; Chief Compliance & G.C. Scott Terrillion , and VP-Research & Development Menzaghi Frederique Ph.d. .
Cara Therapeutics Inc (CARA) Insider Trades Summary
Over the past 18 months, Christopher Posner made 7 insider transaction in Cara Therapeutics Inc (CARA) with a net sale of 60,412. Other recent insider transactions involving Cara Therapeutics Inc (CARA) include a net sale of 5,476 shares made by Joana Goncalves , a net sale of 5,236 shares made by Scott Terrillion , and a net sale of 2,993 shares made by Menzaghi Frederique Ph.d. .
In summary, during the past 3 months, insiders sold 3,668 shares of Cara Therapeutics Inc (CARA) in total and bought 0 shares, with a net sale of 3,668 shares. During the past 18 months, 74,117 shares of Cara Therapeutics Inc (CARA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 74,117 shares.
Cara Therapeutics Inc (CARA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Cara Therapeutics Inc Insider Transactions
Christopher Posner Mailing Address
Above is the net worth, insider trading, and ownership report for Christopher Posner. You might contact Christopher Posner via mailing address: C/o Cara Therapeutics, Inc., 4 Stamford Plaza, 107 Elm Street, 9th Fl, Stamford Ct 06902.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
